

DAFTAR PUSTAKA

1. World Health Organization. Sepsis [Internet]. 2024. Available from: <https://www.who.int/news-room/fact-sheets/detail/sepsis>
2. Menteri Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Nomor: HK.01.07-MENKES-4722-2021 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Sepsis Pada Anak. Kementerian Kesehatan Republik Indones. 2021;1–55.
3. van der Veer MAA, Smits A, de Haan TR, Franken LGW, van Kaam AH, Hodiamont CJ, et al. Amikacin dosing in neonates: evaluation of target attainment using a simplified and complex pharmacokinetic model-derived dosing regimen in clinical practice. *Antimicrob Agents Chemother.* 2025;69(4):1–10.
4. Salsabila K, Toha NMA, Rundjan L, Pattanittum P, Sirikarn P, Rohsiswatmo R, et al. Early-onset neonatal sepsis and antibiotic use in Indonesia: a descriptive, cross-sectional study. *BMC Public Health* [Internet]. 2022;22(1):1–12. Available from: <https://doi.org/10.1186/s12889-022-13343-1>
5. Kereh T, Wilar R, Tatura SNN. Analisis Penggunaan Antibiotik pada Pasien Sepsis Neonatorum di Neonatal Intensive Care Unit RSUP Prof. Dr. R. D. Kandou Manado. *e-CliniC.* 2019;8(1):21–6.
6. Lola Azyenela, Juni Fitrah SNPP. Evaluasi Penggunaan Antibiotik Pada Pasien Sepsis Neonatus di RSUP DR. M. Djamil Padang Tahun 2021-2022. *J Farm SYIFA.* 2025;3(2):94–101.
7. Pauwels, S. ; Allegaert K. Therapeutic Drug Monitoring in Neonates. *BMJ.* 2016;0:1–5.
8. Limato R, Broom A, Nelwan EJ, Hamers RL. A qualitative study of barriers to antimicrobial stewardship in Indonesian hospitals: governance , competing interests , cost , and structural vulnerability. *Antimicrob Resist Infect Control* [Internet]. 2022;1–10. Available from: <https://doi.org/10.1186/s13756-022-01126-7>
9. Boscarino G, Romano R, Iotti C, Tegoni F, Perrone S, Esposito S. An Overview of Antibiotic Therapy for Early- and Late-Onset Neonatal Sepsis: Current Strategies and Future Prospects. *Antibiotics.* 2024;13(3):1–12.
10. Hayes R, Hartnett J, Semova G, Murray C, Murphy K, Carroll L, et al. Neonatal sepsis definitions from randomised clinical trials. *Pediatr Res* [Internet]. 2023;93(5):1141–8. Available from: <http://dx.doi.org/10.1038/s41390-021-01749-3>
11. Kariniotaki C, Thomou C, Gkentzi D, Panteris E, Dimitriou G, Hatzidaki E.

- Neonatal Sepsis: A Comprehensive Review. *Antibiotics*. 2025;14(1):1–24.
12. Tumuhameye J, Sommerfelt H, Bwanga F, Ndeezi G, Mukunya D, Napyo A, et al. Neonatal sepsis at Mulago national referral hospital in Uganda: Etiology, antimicrobial resistance, associated factors and case fatality risk. *PLoS One* [Internet]. 2020;15(8 August):1–14. Available from: <http://dx.doi.org/10.1371/journal.pone.0237085>
 13. Rafi MA, Miah MMZ, Wadood MA, Hossain MG. Risk factors and etiology of neonatal sepsis after hospital delivery: A case-control study in a tertiary care hospital of Rajshahi, Bangladesh. *PLoS One* [Internet]. 2020;15(11 November):1–14. Available from: <http://dx.doi.org/10.1371/journal.pone.0242275>
 14. Agudelo-Pérez S, Fernández-Sarmiento J, Rivera León D, Peláez RG. Metagenomics by next-generation sequencing (mNGS) in the etiological characterization of neonatal and pediatric sepsis: A systematic review. *Front Pediatr*. 2023;11(March):1–15.
 15. Fleischmann C, Reichert F, Cassini A, Horner R, Harder T, Markwart R, et al. Global incidence and mortality of neonatal sepsis: A systematic review and meta-analysis. *Arch Dis Child*. 2021;106(8):745–52.
 16. Raturi A, Chandran S. Neonatal Sepsis: Aetiology, Pathophysiology, Diagnostic Advances and Management Strategies. *Clin Med Insights Pediatr*. 2024;18.
 17. Kumar CK, Sands K, Walsh TR, O'Brien S, Sharland M, Lewnard JA, et al. Global, regional, and national estimates of the impact of a maternal *Klebsiella pneumoniae* vaccine: A Bayesian modeling analysis. *PLoS Med* [Internet]. 2023;20(5 May):1–17. Available from: <http://dx.doi.org/10.1371/journal.pmed.1004239>
 18. Darlow CA, da Costa RMA, Ellis S, Franceschi F, Sharland M, Pidcock L, et al. Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. *Pediatr Drugs* [Internet]. 2021;23(5):465–84. Available from: <https://doi.org/10.1007/s40272-021-00465-z>
 19. Darlow CA, Farrington N, Johnson A, McEntee L, Unsworth J, Jimenez-Valverde A, et al. Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance. *J Antimicrob Chemother*. 2022;77(5):1334–43.
 20. Tan, H. T.; Rahardja K. *Obat-Obat Penting: Khasiat, Penggunaan, dan Efek Sampingnya*. 7th ed. Jakarta: PT Elex Media Komputindo; 2015.
 21. Muntasir; Abdulkadir, W. S.; Harun, A. I.; Saksosne, R. X.; Pernandez, S.; Wonga TM. *Antibiotik dan Resistensi Antibiotik*. Yogyakarta: Rizmedia Pustaka Indonesia; 2022.
 22. Etebu, E.; Ariekpar I. *Antibiotics: Classification and Mechanisms of Action*

- with Emphasis on Molecular Perspectives. *Int J Appl Microbiol Biotechnol Res*. 2016;4(6):90–101.
23. Marhamah. Resistensi Bakteri Gram Positif terhadap Antibiotik di UPTD Balai Laboratorium Kesehatan Lampung Tahun 2012–2014. *J Anal Kesehat Politek Kesehat Tanjungkarang*. 2016;5(1):494–503.
 24. Andiarna, F.; Hidayati, I.; Agustina E. Pendidikan Kesehatan tentang Penggunaan Antibiotik secara Tepat dan Efektif sebagai Upaya Mengatasi Resistensi Obat. *J Community Engagem Employ*. 2020;2(1):15–22.
 25. Ihsan, S.; Kartina, K.; Akib NI. Studi Penggunaan Antibiotik Non Resep di Apotek Komunitas Kota Kendari. *Media Farm*. 2016;13(2):271–84.
 26. Cesur, S.; Demiroz AP. Review Article: Antibiotics and The Mechanisms of Resistance to Antibiotics. *Med J Islam World Acad Sci*. 2013;21(4):138–42.
 27. Tim Penyusun Pedoman Pelayanan Kefarmasian untuk Terapi Antibiotik. *Pedoman Pelayanan Kefarmasian untuk Terapi Antibiotik*. Jakarta; 2011.
 28. Raaijmakers J, Schildkraut JA, Hoefsloot W, van Ingen J. The role of amikacin in the treatment of nontuberculous mycobacterial disease. *Expert Opin Pharmacother*. 2021;22(15):1961–74.
 29. Seely SM, Parajuli NP, De Tarafder A, Ge X, Sanyal S, Gagnon MG. Molecular basis of the pleiotropic effects by the antibiotic amikacin on the ribosome. *Nat Commun*. 2023;14(1):1–12.
 30. Matcha S, Dillibatcha J, Raju AP, Chaudhari BB, Moorkoth S, Lewis LE, et al. Predictive Performance of Population Pharmacokinetic Models for Amikacin in Term Neonates. *Pediatr Drugs [Internet]*. 2023;25(3):365–75. Available from: <https://doi.org/10.1007/s40272-023-00564-z>
 31. Severino N, Urzúa S, Ibacache M, Paulos C, Cortínez L, Toso A, et al. Population pharmacokinetics of amikacin in suspected cases of neonatal sepsis. *Br J Clin Pharmacol*. 2023;89(7):2254–62.
 32. Rouchmana S, Wahyono D, Rahmawati F. Evaluasi Regimen Dosis Amikasin dan Kejadian Efek Nefrotoksik Pada Penggunaan Antibiotik Amikasin di Rumah Sakit Yogyakarta. *Maj Farm*. 2021;17(3):355–64.
 33. Korang SK, Safi S, Nava C, Gordon A, Gupta M, Greisen G, et al. Antibiotic regimens for early-onset neonatal sepsis. *Cochrane Database Syst Rev*. 2021;2021(5).
 34. Stocker M, Rosa-Mangeret F, Agyeman PKA, McDougall J, Berger C, Giannoni E. Management of neonates at risk of early onset sepsis: a probability-based approach and recent literature appraisal: Update of the Swiss national guideline of the Swiss Society of Neonatology and the Pediatric Infectious Disease Group Switzerland. *Eur J Pediatr [Internet]*. 2024;183(12):5517–29. Available from: <https://doi.org/10.1007/s00431->

024-05811-0

35. Kementerian Kesehatan Republik Indonesia. Petunjuk teknis pelayanan kefarmasian di rumah sakit. Jakarta; 2019. 105–106 p.
36. Kementerian Kesehatan Republik Indonesia (Kemenkes RI). Kementerian Kesehatan Republik Kesehatan (Kemenkes RI). 2025. Kategori Usia Bayi dan Balita <5 Tahun. Available from: <https://ayosehat.kemkes.go.id/kategori-usia/bayi-dan-balita>
37. Kementerian Kesehatan Republik Indonesia (Kemenkes RI). Lampiran Terminologi Neonatus [Internet]. 2024. Available from: <https://satusehat.kemkes.go.id/platform/docs/id/terminologi/lampiran-terminologi/neonatus-prio/>
38. Ikatan Dokter Anak Indonesia. Hipotermia Pada Bayi Baru Lahir: Kapan Harus Membawa Bayi Ke Dokter? [Internet]. 2016. Available from: <https://www.idai.or.id/artikel/klinik/pengasuhan-anak/hipotermia-pada-bayi-baru-lahir-kapan-harus-membawa-bayi-ke-dokter>
39. Medscape. Leukocyte Count (WBC) [Internet]. 2025. Available from: <https://emedicine.medscape.com/article/2054452-overview>
40. Sullivan BA. Vital signs as physiometers of neonatal sepsis. 2021;91(1):273–82.
41. Noah FN, Doya LJ. Perinatal Risk Factors and Early Onset of Neonatal Sepsis. 2022;
42. Miranda S, Harahap A, Husada D, Reza M. Risk factors for mortality due to neonatal sepsis: A systematic review and meta-analysis. F1000Research. 2024;13:1569.
43. Folgore L, Bielicki J, Heath PT SM. Antimicrobial-resistant Gram-negative infections in neonates: burden of disease and challenges in treatment. *Curr Opin Infect Dis*. 2017;30(3):281–8.
44. World Health Organization. Global antimicrobial resistance and use surveillance system (GLASS) report 2023. Geneva; 2023.
45. Care I, Roger C, Louart B, Elotmani L, Barton G, Escobar L, et al. An international survey on aminoglycoside practices in critically ill patients : the AMINO III study. 2021;
46. Duszynska W, Taccone FS, Hurkacz M, Kowalska-krochmal B, Wiela-hoje A, Kübler A. Therapeutic drug monitoring of amikacin in septic patients. 2013;
47. van Donge T, Pfister M, Bielicki J, Rodieux F, Gonzalez D van den AJ. Quantitative analysis of gentamicin and amikacin pharmacokinetics in neonates and young infants. *Clin Pharmacokinet*. 2019;59(3):393–409.

48. Medjebeur Hanna, R., Levy, M., Bille, E., Al. E. Assessment of the Effects of a High Amikacin Dose on Plasma Peak Concentration in Critically Ill Children. *Pediatr Drugs*. 2021;23:395–401.
49. Steffens NA, Zimmermann ES, Azeredo FJ, Linden R, Finatto LJ, Hahn RZ, et al. Therapeutic Drug Monitoring-Based Population Pharmacokinetics of Amikacin in Patients at a Teaching Hospital. 2025;1–14.
50. Pacifici G. Clinical pharmacology of amikacin in neonates: a review. *Int J Pediatr*. 2015;1:1–7.
51. World Health Organization. WHO Model Formulary for Children 2010. Geneva; 2010.
52. Hennig S, Huttner A HG. Aminoglycoside dosing and monitoring in neonates: an updated review. *J Antimicrob Chemother*. 2021;76(3):559–67.
53. Thakur K, Gupta P KR. Association between antibiotic duration and clinical outcomes in neonatal sepsis. *Pediatr Infect Dis J*. 2022;41(6):136–43.
54. Lee SY, Kang SJ, Oh H et al. Clinical outcomes and antibiotic duration in neonatal Gram-negative sepsis: a multicenter study. *J Pediatr Infect Dis Soc*. 2024;13(1):42–50.
55. Fatima B, Shafique MF, Murad M, Irfan I, Mehmood A, Nadeem T, et al. Association of Admission Temperature and Outcome among Neonates with Sepsis in a Tertiary Care Hospital. 2024;(4):636–41.
56. Joshi, Rohan and Kommers, Deedee and Oosterwijk, Laurien and Feijs, Loe and van Pul, Carola and Andriessen P. Predicting Neonatal Sepsis Using Features of Heart Rate Variability, Respiratory Characteristics, and ECG-Derived Estimates of Infant Motion. *IEEE J Biomed Heal Informatics*. 2020;24(3):681–92.
57. Koppens, HugoJ. W, DouweH.Visser, Denswil NP, Kaam AH van, Lutterman CA. Heart Rate Characteristics Monitoring for Late-Onset Sepsis in Preterm Infants : A Systematic Review. 2023;548–57.
58. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. *Intensive Care Med*. 2021;47(11):1181–247.
59. van der Poll T, Shankar-Hari M WW. The immunology of sepsis. *Immunity*. 2021;54(11):2450–64.
60. Wynn JL, Polin RA. Progress in the management of neonatal sepsis: the importance of a consensus definition. *Nat Publ Gr [Internet]*. 2017;83(1–1):13–5. Available from: <http://dx.doi.org/10.1038/pr.2017.224>
61. Wangaya R. Hubungan bayi berat lahir rendah dan prematuritas dengan kejadian sepsis neonatorum di. 2023;14(1):5–9.